BETHESDA, Md., March 27, 2014 /PRNewswire/ -- Northwest
Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology
company developing non-toxic DCVax® personalized immune therapies
for cancer, announced today that Linda
Powers, CEO, will present at the 4th Annual
"Cancer Immunotherapy: A Long-Awaited Reality" conference being
held at the New York Academy of Medicine in New York City on Thursday, March 27 at 2:45
pm ET. During her presentation, Ms. Powers will provide an
overview of the Company's DCVax® cancer vaccine platform
technology, product pipeline and clinical programs with DCVax-L and
DCVax-Direct.
There will be a live audio webcast of this presentation at:
http://nwbio.com/webcasts/
About the 4th Annual "Cancer Immunotherapy: A
Long-Awaited Reality" Conference: Hosted by Maidstone Life Sciences
LLC, the 4th Annual "Cancer Immunotherapy: A Long-Awaited Reality"
conference event unites key opinion leaders in Immuno-oncology,
Wall Street research analysts, venture capitalists, institutional
investors, media, and company executives to engage in discussions,
exchange information, highlight opportunities, and showcase leading
companies in the field of Immuno-oncology.
About Northwest Biotherapeutics
Northwest Biotherapeutics is developing cancer vaccines designed
to treat a broad range of solid tumor cancers more effectively than
current treatments, and without the side effects of chemotherapy
drugs. NW Bio's proprietary manufacturing technology enables
the Company to produce its personalized vaccine in an efficient,
cost-effective manner. The Company has a broad platform
technology for DCVax dendritic cell-based vaccines. The
Company's lead product, DCVax-L, is currently in a 312-patient
Phase III trial in the U.S. and Europe for patients with newly diagnosed
Glioblastoma multiforme (GBM), the most aggressive and lethal brain
cancer. The Company's second product, DCVax-Direct, is
currently in a 60-patient Phase I/II trial for direct injection
into all types of inoperable solid tumor cancers. The Company
has also conducted a small Phase I/II trial with DCVax for
metastatic ovarian cancer together with the University of
Pennsylvania. The Company previously received clearance from
the FDA for a 612-patient Phase III trial with its third product,
DCVax-Prostate, for late stage prostate cancer.
Disclaimer
Statements made in this news release that are not historical
facts, including statements concerning future treatment of patients
using DCVax and future clinical trials, are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as "expect," "believe,"
"intend," "plan," "continue," "may," "will," "anticipate," and
similar expressions are intended to identify forward-looking
statements. Actual results may differ materially from those
projected in any forward-looking statement. Specifically,
there are a number of important factors that could cause actual
results to differ materially from those anticipated, such as the
Company's ability to raise additional capital, risks related to the
Company's ability to enroll patient s in its clinical trials and
complete the trials on a timely basis, the uncertainty of the
clinical trials process, uncertainties about the timely performance
of third parties, and whether the Company's products will
demonstrate safety and efficacy. Additional information on
these and other factors, including Risk Factors, which could affect
the Company's results, is included in its Securities and Exchange
Commission ("SEC") filings. Finally, there may be other
factors not mentioned above or included in the Company's SEC
filings that may cause actual results to differ materially from
those projected in any forward-looking statement. You should not
place undue reliance on any forward-looking statements. The
Company assumes no obligation to update any forward-looking
statements as a result of new information, future events or
developments, except as required by securities laws.
Logo -
http://photos.prnewswire.com/prnh/20110329/SF73084LOGO
SOURCE Northwest Biotherapeutics, Inc.